PHARMACEUTICALS: RESTRICTIONS IN USE AND AVAILABILITY



Essential Medicines and Pharmaceutical Policies Quality Assurance and Safety: Medicines Health Systems and Services

PHARMACEUTICALS: RESTRICTIONS IN USE AND AVAILABILITY

Prepared within the context of the United Nations publication

"Consolidated List of Products whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or Not Approved by Governments"



Update of the Twelfth Issue - 2008

Essential Medicines and Pharmaceutical Policies Quality Assurance and Safety: Medicines Health Systems and Services

© World Health Organization 2008

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: 1). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Marketing and Dissemination, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

This text is the update to the Twelfth Issue of the United Nations Consolidated List of Products whose Consumption and/or Sale have been Banned, Withdrawn, Severely Restricted or Not Approved by Governments - Pharmaceuticals (UN General Assembly Resolutions 37/137, 1982; 38/149, 1983; 39/229, 1984; 44/226, 1989). It is offered as a service to drug regulators, the pharmaceutical industry, and to everyone interested in assuring the safe and rational use of drugs. It complements and consolidates other drug-related information issued by the World Health Organization, including the WHO Rapid Alerts, WHO Pharmaceuticals Newsletter and the quarterly subscription journal WHO Drug Information.

Scope and presentation

This volume presents information on new national regulatory decisions, and on voluntary withdrawal of products by manufacturers on grounds of safety, that were reported to WHO up to October 2008.

Products are listed alphabetically within sections; International Nonproprietary Names (INNs) have been used whenever possible. Each product entry includes, where available, the Chemical Abstracts Service registry number (CAS number); synonyms including other generic names and chemical names; the effective date on which the regulation came into force; a summary of regulatory measures taken by governments; brief explanatory comments where necessary; and legal and bibliographical references.

While the information cannot be regarded as exhaustive, either in terms of products or regulatory measures, it covers regulatory actions taken by a total of 27 governments on 88 products. It should be noted, none the less, that decisions taken by a limited number of governments on a specific product may not be representative of the positions of other governments. Moreover, the fact that a given product is not listed as regulated by a country does not necessarily mean that it is permitted in that country; it may mean that the relevant regulatory decision has not been communicated to WHO or that the product has not been submitted for registration. The efficacy of products listed is not addressed, but is an aspect that may be crucial when a government is considering regulatory action.

Criteria for the inclusion of products in the Consolidated List were developed in 1985 and revised in the light of the comments received from governments. However, governments' interpretation of the criterion "severely restricted", in particular, continues to vary widely, leading to considerable unevenness in reporting. When necessary, additional information and/or clarification have been requested from governments; products which clearly do not meet the criteria have been omitted after consultation with governments. Information received from non-governmental organizations has, in each case, been verified with governments.

The information provided also includes references to relevant legal or statutory documents that enable the user to ascertain the legal context and scope of the regulations. Such references cannot be given for most entries relating to specific pharmaceutical products since the relevant licenses are often made or amended by an administrative decision which is not published. Brief explanatory comments also appear, where necessary, to clarify certain regulatory actions and put them into broader context.

Table of Contents

Alphabetical listing

Monocomponent Products

Product N	Name: Acetylsalicylic acid	1
Product N	Name: Alefacept	1
Product N	lame: Amlodipine	1
Product N	Name: Aprotinin	2
Product N	Name: Astemizole	2
Product N	lame: Buflomedil	2
Product N	lame: Cabergoline	3
Product N	lame: Carbamazepine	3
Product N	Name: Ceftriaxone	4
Product N	Name: Cinacalcet	4
Product N	lame: Cisapride	5
Product N	lame: Clobutinol	5
Product N	lame: Codeine	5
Product N	lame: Desmopressin nasal spray	6
Product N	Name: Dolasetron	7
Product N	Name: Ephedrine	7
Product N	Name: Ergometrine	7
Product N	lame: Gatifloxacin	8
Product N	lame: Glucosamine	8
Product N	lame: Hydromorphone hydrochloride	8
Product N	lame: Interferon-gamma-1b	9
Product N	lame: Isotretinoin	9
Product N	lame: Ketamine1	0
Product N	lame: Ketoconazole1	1
Product N	Name: Lamotrigine1	1
Product N	Name: I-arginine1	1
Product N	Name: Lidocaine1	2
Product N	Name: Lindane1	2
Product N	Name: Lumiracoxib1	3
Product N	Name: Meloxicam1	4
Product N	Name: Meprobamate1	4
Product N	Name: Metamizole sodium1	5
Product N	Name: Metoclopramide1	6
Product N	Name: Natalizumab1	6
Product N	lame: Nevirapine1	7
Product N	lame: Nimesulide1	7

Product Name: Nitrofural	19
Product Name: Parecoxib	19
Product Name: Pemoline	20
Product Name: Pergolide	20
Product Name: Phenylpropanolamine	21
Product Name: Piroxicam	22
Product Name: Promethazine	22
Product Name: Pseudoephedrine	23
Product Name: Quinine	23
Product Name: Rimonabant	24
Product Name: Rofecoxib	24
Product Name: Rosiglitazone	25
Product Name: Sargramostim	26
Product Name: Sulfanilamide	26
Product Name: Technetium (99mTc) fanolesomab	26
Product Name: Tegaserod	27
Product Name: Telithromycin	28
Product Name: Terfenadine	29
Product Name: Thioridazine	30
Product Name: Tizanidine	31
Product Name: Trimethobenzamide	31
Product Name: Valdecoxib	32
Product Name: Venlafaxine	33
Product Name: Veralipride	33
Product Name: Ximelagatran	34
Combination of Products	
Product Name: Alimemazine - Paracetamol teething mixture	34
Product Name: Atazanavir-Ritonavir	34
Product Name: Chlorproguanil and Dapsone	34
Product Name: Cyproterone acetate and ethinylestradiol	35
Product Name: Dextropropoxyphene-paracetamol	35
Product Name: Estradiol-testosterone injection	36
Product Name: Ingalipt (Combination aerosol)	36
Product Name: Metamizole, pitofenone and fenpiverinium	37

Group Products

Angiotensin II receptor antagonists	38
Product Name: Attention-Deficit/Hyperactivity Disorder (ADHD) drugs	38
Product Name: Alendronic acid and other bisphosphonates	39
Product Name: Antidepressants	39
Product Name: Antiretroviral agents	40
Product Name: Betamethasone and other potent corticosteroids for topical u	_
Product Name: Black Cohosh (Cimicifugae racemosae)-containing products	
Product Name: Clobutinol-containing cough preparations	
Product Name: Cyclo-oxygenase-2 (COX-2) Inhibitors	
Product Name: Drug-eluting stents	
Product Name: Ephedrine and pseudoephedrine containing OTC products	43
Product Name: Nasal/oropharyngeal antibiotics	4 4
Product Name: Non steroidal anti-inflammatory agents (NSAIDs)	4 4
Product Name: Products containing Ginseng	45
Product Name: Propolis and Royal Jelly Products	45
Product Name: Risperidone and other atypical antipsychotics	46
Product Name: Thiazolidinedione antidiahetics	46

预览已结束,完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5_29372

